Browse Studies — Arctuva

Phase 2

Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors

This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell dea…

Lung CancerNon-small Cell Lung CancerMetastatic Lung Cancer+4 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07630168

Phase 2

The 5-Fluorouracil Response and Optimization STudy (The FROST Trial): A Randomized Phase II Trial of Two Dosage Regimens (2D-Q2W vs 4D-Q3W) of 5-Fluorouracil (5-FU) in Patients With Platinum and PD-1 Inhibitor Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patient…

Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Head and Neck

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07419464

Phase 1

A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients…

Head and Neck NeoplasmsCarcinoma, Squamous CellNeoplasm Recurrence, Local+3 more

Estimated

~$10 – $6,250

University of ChicagoNCT06912087